Biomea Fusion (BMEA) vs Nomad Power Solutions (NMAD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Nomad Power Solutions (NMAD) has outperformed Biomea Fusion (BMEA) over the past year, losing 13.8% versus a loss of 42.5%. Over five years, NMAD leads with a -79.3% price change compared with -92.1% for BMEA. Biomea Fusion is the larger company by market cap ($62.8 million vs $62.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | NMAD |
|---|---|---|
| Share price | $0.8689 | $3.88 |
| Market cap | $62.82M | $62.47M |
| 1-day change | +3.89% | -5.13% |
| YTD return | -29.93% | -1.27% |
| 1-year return | -42.46% | -13.78% |
| 5-year return | -92.09% | -79.25% |
| EPS (TTM) | $-0.29 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-61.80M | $-6.08M |
| 52-week high | $2.24 | $8.38 |
| 52-week low | $0.7995 | $2.36 |
| Distance from 52-week high | -61.16% | -53.70% |
| Analyst consensus | buy | — |
| Avg. price target upside | +705.62% | — |
| Average volume | 1.93M | 256.04K |
| Shares outstanding | 72.30M | 16.10M |
| Employees | 37 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NMAD has outperformed BMEA by 28.7 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Nomad Power Solutions
NMAD stock →NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.
Health Care · Biotechnology: Pharmaceutical Preparations
BMEA vs NMAD FAQ
Which is bigger, Biomea Fusion or Nomad Power Solutions?
Biomea Fusion (BMEA) is larger, with a market capitalization of $62.82M compared with $62.47M for Nomad Power Solutions (NMAD).
Which stock has performed better over the past year, BMEA or NMAD?
NMAD returned -13.78% over the past 12 months, compared with -42.46% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Nomad Power Solutions in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.